COMP <GO>
INFU vs MRK // GROSS PROFIT MARGIN
InfuSystems Holdings Inc. (NYSE) VS. Merck & Company Inc. (NYSE) • 15-METRIC TALLY: INFU 4
— MRK 9
▲ GROSS PROFIT MARGIN LEADER: MRK
LAST: $14.07 (-2.63%) • MKT CAP: $287.8M
gross-margins
56.00%
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
gross-margins
74.80%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (INFU VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | INFU | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin ACTIVE | 56.00% | 74.80% | -18.80 | MRK | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 12.80% | 20.70% | -7.90 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation | 24.5x | 15.3x | +9.20 | MRK | /valuation <GO> |
| Free Cash Flow Yield | 8.29% | 3.42% | +4.87 | INFU | /fcf-yield <GO> |
| Operating Margin | 8.30% | 34.30% | -26.00 | MRK | /operating-margins <GO> |
| Net Profit Margin | 4.60% | 28.10% | -23.50 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) | 6.40% | 1.30% | +5.10 | INFU | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 5.16 | 5.19 | -0.03 | MRK | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 7/9 | +2.00 | INFU | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 63.5 | 51.7 | +11.80 | INFU | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.92 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 40.4x | 18.4x | +22.00 | MRK | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $287.8M | $361.02B | -$360.73B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | INFU REV | MRK REV | INFU GROSS % | MRK GROSS % | INFU FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $143.4M | $65.01B | 56.0% | 74.8% | $23.8M | $12.36B |
| FY 2024 | $134.9M | $64.17B | 52.2% | 76.3% | $19.4M | $18.10B |
| FY 2023 | $125.8M | $60.12B | — | — | $11.2M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
INFU // BETA —
MRK // BETA 0.92